Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

B Cell and BAFF Dependence of IFN- -Exaggerated Disease in Systemic Lupus Erythematosus-Prone NZM 2328 Mice

(2011) N. Jacob et al.   JOURNAL OF IMMUNOLOGY

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Constitutive overexpression of BAFF in autoimmune-resistant mice drives only some aspects of systemic lupus erythematosus-like autoimmunity

(2010) William Stohl et al.   ARTHRITIS AND RHEUMATISM

B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B cell maturation antigen-immunoglobulin

(2010) Stacey R Dillon et al.   ARTHRITIS RESEARCH & THERAPY

Accelerated Pathological and Clinical Nephritis in Systemic Lupus Erythematosus-Prone New Zealand Mixed 2328 Mice Doubly Deficient in TNF Receptor 1 and TNF Receptor 2 via a Th17-Associated Pathway

(2009) N. Jacob et al.   JOURNAL OF IMMUNOLOGY

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

(2008) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM

APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells

(2008) E. Belnoue et al.   BLOOD

BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact

(2008) J. L. Scholz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA